Recorded device evidence

Tablo® Hemodialysis System; TabloCart™ with Prefiltration Drawer (K232776): indications, design and recorded evidence

The acquired K232776 file contains product-specific indications and users, design and operating principle, non-clinical evidence actually described, performance evidence actually described, clinical evidence or its stated absence sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 32 selected decisions under primary code KDI. 32 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

Calendar elapsed days: lower quartile 118.2, median 215.5, upper quartile 252.0. These are recorded calendar differences, not active FDA review time.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K232776 ↗ · this pageTablo® Hemodialysis System; TabloCart™ with Prefiltration Drawer2023-09-11 → 2024-05-03235Traditional
K261267 ↗Careflux H60;Careflux H70;Careflux V5002026-04-16 → 2026-07-2499Traditional
K252377 ↗NxStage System One with NxView2025-07-30 → 2026-05-15289Traditional
K260533 ↗ELISIO™-H2026-02-17 → 2026-03-1930Special
K252459 ↗multiFlux 130 (F00013123); multiFlux 160 (F00013124)2025-08-05 → 2026-02-10189Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K232776 · PDF page 6 ↗ Source 2

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K232776 · PDF page 9 ↗ Source 3

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Non-clinical evidence actually described

K232776 · PDF page 15 ↗ Source 4

Additional bench testing was conducted to support the accessory TabloCart with Prefiltration.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

Performance evidence actually described

K232776 · PDF page 14 ↗ Source 5

The software for the Tablo Hemodialysis System is not impacted by use, or non-use, of the TabloCart
with Prefiltration.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Clinical evidence or its stated absence

K232776 · PDF page 15 ↗ Source 4

No clinical studies were conducted to support the updated Tablo                ® Hemodialysis System and TabloCart
with Prefiltration Drawer.

Compare with your product: Preserve whether the summary describes clinical evidence or says none was performed. This recorded case does not determine whether your product needs clinical evidence.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {'uncertain_pdf_page': 1}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK232776 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryTablo® Hemodialysis System; TabloCart™ with Prefiltration Drawer [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantOutset Medical, Inc. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeKDI [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2024-05-03 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2023-09-11 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Non-clinical evidence actually described — what differs in our product?

    Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

    Useful evidence: Existing protocols/results and design-specific evidence gaps, with standard editions and scope reviewed separately.

  4. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

  5. Clinical evidence or its stated absence — what differs in our product?

    Preserve whether the summary describes clinical evidence or says none was performed. This recorded case does not determine whether your product needs clinical evidence.

    Useful evidence: Your proposed claims and supporting evidence, plus a reviewed rationale for clinical-evidence needs.

Work packages and dependencies

What needs to happen first

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[90165] · record 54406b4743f5d327a87525dac84c962d80ebcdcce564bcd0b02e7773947bc99e
  • [6] Complete results array / fda-decision-context:K232776 · record whole dataset partition

FDA 510(k) summary — K232776 ↗

Sat, 04 May 2024 15:34:02 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot b14ef3eac23487d716b0dcfd9f82b6dff29bc6dbc70b1939d46be5cf2bfbc9d2

  • [2] PDF page 6 · record 7752f26fc0c4ca81e7227a44eeead3f00b67c02cfa45e5733402fe4b33a4fbe1
  • [3] PDF page 9 · record 8ba33ba1b8205647f54ee8a83ccaaadbf59822fdf9fd0e1a823bf046e2e34e99
  • [4] PDF page 15 · record 7cfd802c0af7cc44822d3288eee488337bf5002045a43296db0af8cc26a76e35
  • [5] PDF page 14 · record 30bb183d69e940b09e0cad8a4f1db8ae1a433acd4fa3a75b3d7eeafc6b7b478c

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services

Usability / Human Factors Testing